229 related articles for article (PubMed ID: 28576831)
1. Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on
Frazao A; Colombo M; Fourmentraux-Neves E; Messaoudene M; Rusakiewicz S; Zitvogel L; Vivier E; Vély F; Faure F; Dréno B; Benlalam H; Bouquet F; Savina A; Pasmant E; Toubert A; Avril MF; Caignard A
Cancer Immunol Res; 2017 Jul; 5(7):582-593. PubMed ID: 28576831
[TBL] [Abstract][Full Text] [Related]
2. BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis.
Frazao A; Rethacker L; Jeudy G; Colombo M; Pasmant E; Avril MF; Toubert A; Moins-Teisserenc H; Roelens M; Dalac S; Maubec E; Caignard A
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912923
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma.
Khalili JS; Liu S; Rodríguez-Cruz TG; Whittington M; Wardell S; Liu C; Zhang M; Cooper ZA; Frederick DT; Li Y; Zhang M; Joseph RW; Bernatchez C; Ekmekcioglu S; Grimm E; Radvanyi LG; Davis RE; Davies MA; Wargo JA; Hwu P; Lizée G
Clin Cancer Res; 2012 Oct; 18(19):5329-40. PubMed ID: 22850568
[TBL] [Abstract][Full Text] [Related]
4. c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells.
Molfetta R; Quatrini L; Capuano C; Gasparrini F; Zitti B; Zingoni A; Galandrini R; Santoni A; Paolini R
Eur J Immunol; 2014 Sep; 44(9):2761-70. PubMed ID: 24846123
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties.
Ott PA; Henry T; Baranda SJ; Frleta D; Manches O; Bogunovic D; Bhardwaj N
Cancer Immunol Immunother; 2013 Apr; 62(4):811-22. PubMed ID: 23306863
[TBL] [Abstract][Full Text] [Related]
6. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
7. HO-1 downregulation favors BRAF
Furfaro AL; Ottonello S; Loi G; Cossu I; Piras S; Spagnolo F; Queirolo P; Marinari UM; Moretta L; Pronzato MA; Mingari MC; Pietra G; Nitti M
Int J Cancer; 2020 Apr; 146(7):1950-1962. PubMed ID: 31376303
[TBL] [Abstract][Full Text] [Related]
8. NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo.
Jalili A; Mertz KD; Romanov J; Wagner C; Kalthoff F; Stuetz A; Pathria G; Gschaider M; Stingl G; Wagner SN
PLoS One; 2013; 8(7):e69064. PubMed ID: 23935925
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib.
Garbe C; Abusaif S; Eigentler TK
Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
[TBL] [Abstract][Full Text] [Related]
10. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
Ferrari de Andrade L; Ngiow SF; Stannard K; Rusakiewicz S; Kalimutho M; Khanna KK; Tey SK; Takeda K; Zitvogel L; Martinet L; Smyth MJ
Cancer Res; 2014 Dec; 74(24):7298-308. PubMed ID: 25351955
[TBL] [Abstract][Full Text] [Related]
11.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
12. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
13. Varicella-Zoster Virus and Herpes Simplex Virus 1 Differentially Modulate NKG2D Ligand Expression during Productive Infection.
Campbell TM; McSharry BP; Steain M; Slobedman B; Abendroth A
J Virol; 2015 Aug; 89(15):7932-43. PubMed ID: 25995251
[TBL] [Abstract][Full Text] [Related]
14. Everolimus selectively targets vemurafenib resistant BRAF
Ruzzolini J; Peppicelli S; Andreucci E; Bianchini F; Margheri F; Laurenzana A; Fibbi G; Pimpinelli N; Calorini L
Cancer Lett; 2017 Nov; 408():43-54. PubMed ID: 28826720
[TBL] [Abstract][Full Text] [Related]
15. Vemurafenib and trametinib reduce expression of CTGF and IL-8 in
Hartman ML; Rozanski M; Osrodek M; Zalesna I; Czyz M
Lab Invest; 2017 Feb; 97(2):217-227. PubMed ID: 28067893
[TBL] [Abstract][Full Text] [Related]
16. CEACAM1-3S Drives Melanoma Cells into NK Cell-Mediated Cytolysis and Enhances Patient Survival.
Ullrich N; Heinemann A; Nilewski E; Scheffrahn I; Klode J; Scherag A; Schadendorf D; Singer BB; Helfrich I
Cancer Res; 2015 May; 75(9):1897-907. PubMed ID: 25744717
[TBL] [Abstract][Full Text] [Related]
17. BRAF V600E-dependent role of autophagy in uveal melanoma.
Zhao Y; Wang W; Min I; Wyrwas B; Moore M; Zarnegar R; Fahey TJ
J Cancer Res Clin Oncol; 2017 Mar; 143(3):447-455. PubMed ID: 27928645
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
Kundu A; Quirit JG; Khouri MG; Firestone GL
Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
[TBL] [Abstract][Full Text] [Related]
19. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications.
Liu W; Stachura P; Xu HC; Umesh Ganesh N; Cox F; Wang R; Lang KS; Gopalakrishnan J; Häussinger D; Homey B; Lang PA; Pandyra AA
J Exp Clin Cancer Res; 2020 Feb; 39(1):38. PubMed ID: 32085796
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 10 decreases MICA expression on melanoma cell surface.
Serrano AE; Menares-Castillo E; Garrido-Tapia M; Ribeiro CH; Hernández CJ; Mendoza-Naranjo A; Gatica-Andrades M; Valenzuela-Diaz R; Zúñiga R; López MN; Salazar-Onfray F; Aguillón JC; Molina MC
Immunol Cell Biol; 2011 Mar; 89(3):447-57. PubMed ID: 20714339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
